SAR441344 IV ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1
49	Systemic lupus erythematosus	1

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,342 /  Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04879628 (ClinicalTrials.gov)	June 7, 2021	6/5/2021	Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis	A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: SAR441344 IV;Drug: placebo IV;Drug: SAR441344 SC;Drug: placebo SC;Drug: MRI contrast-enhancing preparations	Sanofi	NULL	Recruiting	18 Years	55 Years	All	120	Phase 2	United States;Bulgaria;Canada;Czechia;France;Germany;Spain;Turkey;Ukraine

49. Systemic lupus erythematosus

---

Clinical trials : 946 /  Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05039840 (ClinicalTrials.gov)	October 2021	1/9/2021	Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus	Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study	Systemic Lupus Erythematosus	Drug: SAR441344 IV;Drug: SAR441344 SC;Drug: Placebo IV;Drug: Placebo SC	Sanofi	NULL	Recruiting	18 Years	70 Years	All	116	Phase 2	United States